
    
      Approximately 600 subjects who meet inclusion/exclusion criteria will be enrolled in the
      prospective, non-randomized, observational study. Sample size is based on having an adequate
      overall number of subjects to assess the T-SPOT.PRT endpoint (350) and the T-SPOT.CMV
      endpoint (250) in the defined populations. Subjects may be enrolled from pre-transplantation
      to post-transplantation up to completion of antiviral prophylaxis.

      Study duration: 37 months; 25 months to enroll all subjects with 12 months (365 days) of
      patient participation.

      Study population:

      All subjects enrolled in this study will be men or women, aged 18 years or older and
      recipients of a first or subsequent renal transplant.
    
  